Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDE196 in Solid Tumors With GNAQ/11 Mutations or PRKC Fusions
NCT03947385Phase 2Recruiting
- Sponsor
- IDEAYA Biosciences
- Start
- Jun 2019
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of darovasertib in Uveal melanoma (UM), cutaneous melanoma (CM), colorectal cancer (CRC), solid tumor, sponsored by IDEAYA Biosciences. Started Jun 2019; status: recruiting.
02
Drugs
darovasertib
03
Conditions
Uveal melanoma (UM)cutaneous melanoma (CM)colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT03947385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03947385.